Clinical‑Stage Biopharma Revelyx Bio Launches with Exclusive Global License for YY003 – Ready‑to‑Use Recombinant Botulinum Toxin Type A
Clinical‑stage biopharmaceutical company Revelyx Bio, Inc. announced on August 31, 2026 its official launch, backed...